Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ MichiganfiledCriticalUniv Michigan
Publication of UY33324ApublicationCriticalpatent/UY33324A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Se proporcionan en la presente memoria métodos para seleccionar y tratar a un sujeto con leucemia, en los que el sujeto se selecciona para tratamiento y se trata con inhibidor de MDM2 debido a que las células de dicho sujeto contienen una mutación FLT-3-ITDMethods for selecting and treating a subject with leukemia are provided herein, in which the subject is selected for treatment and treated with MDM2 inhibitor because the cells of said subject contain a FLT-3-ITD mutation.
UY33324A2010-04-092011-04-08
BIOMARCATORS FOR MDM2 INHIBITORS FOR USE IN THE TREATMENT OF DISEASE
UY33324A
(en)
COMBINED THERAPIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNAL NEOPLASIAS USING PI3K / MTOR PYRIDOPIRIMIDINONE INHIBITORS WITH BENDAMUSTINE AND / OR RITUXIMAB.
Method for treating a CDI in a mammal that is undergoing simultaneous antibiotic therapy to combat a different infection, which includes the use of fidaxomycin.